The American College of Physicians (ACP) recommends in an evidence-based clinical practice guideline published today in Annals of Internal Medicine that physicians treat women with osteoporosis with bisphosphonates (alendronate, risedronate, or zoledronic acid) or denosumab, a biologic agent. ACP recommends that physicians offer drug treatment with bisphosphonates to reduce the risk for vertebral fracture in men with osteoporosis.